Processing .....please wait.. 
The article has been forwarded.... 
SuperSonic Imagine raises 20 million euros
By siliconindia
Bangalore: SuperSonic Imagine, which provides technology to improve medical diagnosis, has announced a second fund-raising round of 20 million euros, led by Edmond de Rothschild Investment Partners, a new investor in SuperSonic Imagine. Edmond de Rothschild Investment Partners has invested seven million euros alongside Auriga Partners, Credit Agricole Private Equity, NBGI Ventures and BioAm, current investors in the Aix-en-Provence-based startup, who are renewing their financial backing with a further 13 million euro.
This second round follows a seed round of 500,000 euros financed by SuperSonic Imagine founder and CEO Jacques Souquet and Auriga Partners, and a first round of 10 million euros that was led in March 2006 by Credit Agricole Private Equity alongside Auriga Partners, NBGI Ventures and BioAm.
The first round of fund-raising had allowed the company to develop Aixplore, a revolutionary ultrasound system for improved diagnosis of mammary pathologies, in the space of two and a half years.
The result of major technological breakthroughs, SuperSonic Imagine's new ultrasound system has revolutionized medical imaging by measuring tissue elasticity through the previously undetected visualization of shear waves, generated by Aixplorer.
SuperSonic Imagine's technology improves breast lesion diagnosis by identifying millimetric non-palpable lesions and anomalies which, because they are deep-set or located in dense breasts, were previously undetectable.
21 international patents have been submitted and filed for SuperSonic Imagine's new generation ultrasound system, including Professor Mathias Fink's patents at the Waves and Acoustics Laboratory (LOA/CNRS), Arman Sarvazyan's original patents, and those directly registered by SuperSonic Imagine. This technology is solely owned and solely used by SuperSonic Imagine.
"Between now and 2012, we will have adapted this technology to other clinical applications such as prostate, kidney, thyroid or liver, not to mention cardiovascular imaging," stated Jacques Souquet, founder and CEO of SuperSonic Imagine.
